Skip to main
CRDL

Cardiol Therapeutics (CRDL) Stock Forecast & Price Target

Cardiol Therapeutics (CRDL) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cardiol Therapeutics Inc. has demonstrated a strong clinical signal with CardiolRx, achieving statistically significant improvements in left ventricular mass and showing a favorable safety profile that supports ongoing development. The completion of the Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial, along with positive data from the ARCHER program, enhance confidence in the broader therapeutic potential of both CardiolRx and CRD-38 for treating inflammatory heart conditions. These favorable outcomes not only de-risk the company’s recurrent pericarditis program but also improve the appeal of CRD-38 for larger indications such as heart failure, positioning Cardiol Therapeutics for a positive financial outlook.

Bears say

Cardiol Therapeutics Inc. is currently facing a challenging market environment, reflected in its approximately $98 million market capitalization, which suggests that investors are assigning little to no value to the positive indications from its ARCHER trial. This limited valuation may stem from the statistical limitations encountered in the trial, where the primary endpoint narrowly missed significance, raising concerns about the program's efficacy and overall biological activity. Additionally, while CRD-38 aims to differentiate itself by focusing on inflammation and fibrosis, the failure of AZD3427 highlights the inherent risks and complexities associated with therapeutic strategies targeting the heart, indicating a potentially tough road ahead for Cardiol Therapeutics.

Cardiol Therapeutics (CRDL) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cardiol Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cardiol Therapeutics (CRDL) Forecast

Analysts have given Cardiol Therapeutics (CRDL) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Cardiol Therapeutics (CRDL) has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cardiol Therapeutics (CRDL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.